This press release was issued by AstraZeneca.

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next- generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.

The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.

AstraZeneca has a broad portfolio of in-house ADCs including six wholly owned ADCs in the clinic and many more in preclinical development.

As part of AstraZeneca's commitment to driving sustainability in healthcare, the Company will work with Singapore's government and other partners on green solutions for the ADC facility. This facility will be designed to emit zero carbon from its first day of operations.

AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029.

Please refer to the original AstraZeneca press release here: https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html